NewsRoom Articles - Page 1235 of 1409

FridayJun 16, 2017 11:00 am

MYnd Analytics, Inc. (MYAN) Starts Presentation at the 2017 Marcum Microcap Conference

MYnd Analytics (OTC: MYAN) is a predictive analytics company that has developed a cloud based support tool to help physicians reduce trial and error treatment in mental health. The company provides objective clinical decision support to mental healthcare providers for the personalized treatment of multiple behavioral disorders. The company uses its neurometric platform to generate Psychiatric Electroencephalogram Evaluation Registry (PEER) Reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. For more information, visit the company's website at www.myndanalytics.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

FridayJun 16, 2017 10:30 am

Roka Bioscience, Inc. (NASDAQ: ROKA) Starts Presentation at the 2017 Marcum Microcap Conference

Roka Bioscience (NASDAQ: ROKA) is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the food safety industry. The company’s Atlas® System represents a new tier of molecular rapid pathogen testing, offering automation and technology that brings true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come. For more information, visit the company's website at rokabio.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access…

FridayJun 16, 2017 10:30 am

ENDRA Life Sciences, Inc. (NASDAQ: NDRAU) Starts Presentation at the 2017 Marcum Microcap Conference

ENDRA Life Sciences (NASDAQ: NDRAU) develops photo-and thermo-acoustic medical technologies bringing new capabilities to existing ultrasound systems. ENDRA's photo-acoustic solutions help medical researchers screen and modify disease models with high image quality and volume scanning speed. ENDRA has a global installed base of leading institutions using its Nexus-128 system, the only commercially available 3D imaging system for imaging anatomy, physiology and labeled molecular targets. ENDRA's thermo-acoustic technology is being developed for use with existing ultrasound equipment to visualize tissue function, composition, and monitor a variety of therapeutic interventions. For more information, visit the company's website at www.endrainc.com About NetworkNewsWire NetworkNewsWire…

FridayJun 16, 2017 10:30 am

InspireMD, Inc. (NYSE: NSPR) Starts Presentation at the 2017 Marcum Microcap Conference

InspireMD (NYSE: NSPR) was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes. Today, InspireMD is a global company headquartered in Boston, MA. InspireMD seeks to utilize its proprietary MicroNetTM technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures. For more information, visit the company's website at inspiremd.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service…

FridayJun 16, 2017 10:00 am

Orgenesis, Inc. (ORGS) Starts Presentation at the 2017 Marcum Microcap Conference

Orgenesis (OTC: ORGS) is a biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The company's MaSTherCell subsidiary is able to deliver optimized process industrialization capacities to cell therapy companies. MaSTherCell's customers include many of the world's leading pharmaceutical and biotech companies. Orgenesis is a pioneer in the process of trans-differentiation (cell reprograming), whereby an adult cell is converted into another type of cell. Orgenesis has successfully reprogramed human liver cells into glucose-responsive, fully functional, insulin producing cells. For more information, visit the company's website at www.orgenesis.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

FridayJun 16, 2017 10:00 am

VolitionRX Ltd. (NYSE: VNRX) Starts Presentation at the 2017 Marcum Microcap Conference

VolitionRX (NYSE: VNRX) is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. The company’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively since early diagnosis often has the potential to prolong the life of patients. For more information, visit the company's website at www.volitionrx.com About NetworkNewsWire NetworkNewsWire (NNW)…

FridayJun 16, 2017 10:00 am

MagneGas Corporation (NASDAQ: MNGA) Starts Presentation at the 2017 Marcum Microcap Conference

MagneGas (NASDAQ: MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels. These fuels can be used as an alternative to natural gas or for metal cutting. The company's testing has shown that its metal cutting fuel "MagneGas2®" is faster, cleaner and more productive than other alternatives on the market. It is also cost effective and safe to use with little changeover costs. The company currently sells MagneGas2® into the metal working market as a replacement to acetylene. For more information, visit the company's website at www.magnegas.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

FridayJun 16, 2017 10:00 am

NeuroMetrix, Inc. (NASDAQ: NURO) Starts Presentation at the 2017 Marcum Microcap Conference

NeuroMetrix (NASDAQ: NURO) is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy. For more information, visit the company's website at www.neurometrix.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to…

FridayJun 16, 2017 10:00 am

RespireRx Pharmaceuticals, Inc. (RSPI) Starts Presentation at the 2017 Marcum Microcap Conference

RespireRx Pharmaceuticals (OTC: RSPI) is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. The company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress. The company owns patents and patent applications, and holds exclusive licenses, for certain families of chemical compounds that claim the chemical structures and their use in the treatment of these and other disorders. For more information, visit the company's website at www.respirerx.com About NetworkNewsWire NetworkNewsWire (NNW) is an information…

FridayJun 16, 2017 9:30 am

Mateon Therapeutics, Inc. (MATN) Starts Presentation at the 2017 Marcum Microcap Conference

Mateon Therapeutics (OTC: MATN) is a biopharmaceutical company focused on vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents(AAs), which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. The company believes it can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to central tumor cell death while AAs prevent formation of new tumor blood vessels. For more information, visit…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

MYnd Analytics, Inc. (MYAN) Starts Presentation at the 2017 Marcum Microcap Conference

Roka Bioscience, Inc. (NASDAQ: ROKA) Starts Presentation at the 2017 Marcum Microcap Conference

ENDRA Life Sciences, Inc. (NASDAQ: NDRAU) Starts Presentation at the 2017 Marcum Microcap Conference

InspireMD, Inc. (NYSE: NSPR) Starts Presentation at the 2017 Marcum Microcap Conference

Orgenesis, Inc. (ORGS) Starts Presentation at the 2017 Marcum Microcap Conference

VolitionRX Ltd. (NYSE: VNRX) Starts Presentation at the 2017 Marcum Microcap Conference

MagneGas Corporation (NASDAQ: MNGA) Starts Presentation at the 2017 Marcum Microcap Conference

NeuroMetrix, Inc. (NASDAQ: NURO) Starts Presentation at the 2017 Marcum Microcap Conference

RespireRx Pharmaceuticals, Inc. (RSPI) Starts Presentation at the 2017 Marcum Microcap Conference

Mateon Therapeutics, Inc. (MATN) Starts Presentation at the 2017 Marcum Microcap Conference

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsWire Currently Accepts

Company Search

Site Search